According to Fierce Biotech, Iambic Therapeutics is preparing to go public, aiming to carry forward the momentum generated by its recent megaround and a string of partnerships with large pharmaceutical companies. The report does not specify the size or timing of the planned offering.
The IPO would mark a shift from private financing and pharma collaborations toward the public markets. By moving in this direction, the company appears to be trying to sustain the visibility and commercial traction it has built through its recent dealmaking activity.